Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma

Authors

  • YunMi Qiu Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • Kamran Ali Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • HaiYue Lou Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.
  • JingPeng Shan Department of Dermatology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China
  • Liming Wu Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, No.261, Huansha Road, Hangzhou, P. R. China

DOI:

https://doi.org/10.2340/actadv.v101.224

Keywords:

atopic dermatitis, dupilumab, non-Hodgkin’s lymphoma

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377-388.

https://doi.org/10.1016/j.jaad.2019.07.074 DOI: https://doi.org/10.1016/j.jaad.2019.07.074

Chun PIF, Lehman H. Current and future monoclonal antibodies in the treatment of atopic dermatitis. Clin Rev Allergy Immunol 2020; 59: 208-219.

https://doi.org/10.1007/s12016-020-08802-9 DOI: https://doi.org/10.1007/s12016-020-08802-9

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018; 41: 489-509.

https://doi.org/10.1007/s40264-017-0636-9 DOI: https://doi.org/10.1007/s40264-017-0636-9

Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol 2019; 99: 899-900.

https://doi.org/10.2340/00015555-3201 DOI: https://doi.org/10.2340/00015555-3201

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111-1116.

https://doi.org/10.1016/j.jaci.2009.02.028 DOI: https://doi.org/10.1016/j.jaci.2009.02.028

Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opin Drug Saf 2021; 20: 997-1004.

https://doi.org/10.1080/14740338.2021.1939673 DOI: https://doi.org/10.1080/14740338.2021.1939673

Miyashiro D, Vivarelli AG, Goncalves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther 2020; 33: e13880.

https://doi.org/10.1111/dth.13880 DOI: https://doi.org/10.1111/dth.13880

Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 2020; 83: 197-199.

https://doi.org/10.1016/j.jaad.2020.03.050 DOI: https://doi.org/10.1016/j.jaad.2020.03.050

Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol 2004; 84: 327-328.

https://doi.org/10.1080/00015550410025967 DOI: https://doi.org/10.1080/00015550410025967

Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol 2020; 156: 1086-1097.

https://doi.org/10.1001/jamadermatol.2020.1948 DOI: https://doi.org/10.1001/jamadermatol.2020.1948

Downloads

Published

2022-01-04

How to Cite

Qiu, Y., Ali, K., Lou, H., Shan, J., & Wu, L. (2022). Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin’s Lymphoma . Acta Dermato-Venereologica, 102, adv00625. https://doi.org/10.2340/actadv.v101.224